Quantitative measurement of viral load is an important parameter in the management of fi lovirus disease outbreaks because viral load correlates with severity of disease, survival, and infectivity. During the ongoing Ebola virus disease outbreak in parts of Western Africa, most assays used in the detection of Ebola virus disease by more than 44 diagnostic laboratories yielded qualitative results. Regulatory hurdles involved in validating quantitative assays and the urgent need for a rapid Ebola virus disease diagnosis precluded development of validated quantitative assays during the outbreak. Because of sparse quantitative data obtained from these outbreaks, opportunities for study of correlations between patient outcome, changes in viral load during the course of an outbreak, disease course in asymptomatic individuals, and the potential for virus transmission between infected patients and contacts have been limited. We strongly urge the continued development of quantitative viral load assays to carefully evaluate these parameters in future outbreaks of fi lovirus disease.
Introduction
The mononegaviral family Filoviridae currently has eight members, six of which are known to cause human disease. Of these six, the two marburgviruses, Marburg virus and Ravn virus, cause Marburg virus disease (International Classifi cation of Diseases-10 [ICD-10] A98.3); and four ebolaviruses, Bundibugyo virus, Ebola virus, Sudan virus, and Taï Forest virus, cause Ebola virus disease (ICD-10 A98.4).
1 Patients typically present with a range of non-specifi c signs and symptoms, including fever, headache, weak ness, malaise, myalgia, conjunctival injection, gastro intestinal disturbances (eg, abdominal pain, nausea, vomiting, and diarrhoea), and, less frequently, bleeding.
1 Marburg virus disease and Ebola virus disease are impossible to diff erentiate from each other on the basis of clinical observation alone. 2 In the early phases of disease and in the absence of a recognised outbreak, readily distinguishing fi lovirus disease from a host of more common causes of systemic febrile disease-for example malaria, typhoid fever, bacterial gastroenteritis, and other viral haemorrhagic fevers such as severe dengue or Lassa fever-is very diffi cult.
1 Thus, rapid and safe laboratory diagnosis of patients with suspected Marburg virus disease and Ebola virus disease is imperative, and should not rely on fi lovirus culture, which requires specialised biosafety level 4 facilities.
In recent years, the development of fi eld-deployable molecular assays, especially RT-PCR, for the diagnosis of fi lovirus infection has proved to be an invaluable tool for case identifi cation and management, and for general outbreak control. At the peak of the massive and ongoing outbreak of Ebola virus disease in Western Africa, more than 44 laboratories provided such diagnostic services.
3
Serological tests are not particularly useful in diagnosing acute fi lovirus infection, since the presence of IgG might mean little in a fi lovirus-endemic area and IgM can represent diff erent stages of fi loviral disease. Therefore, diagnosing recent fi lovirus infection might require sequential blood draws to ascertain increasing IgM titres. 4 Several rapid antigen detection tests (RDTs) have been developed, such as ReEBOV, SD Q Line, and OraQuick.
5-7 However, RDTs have low sensitivity and specifi city. Additionally, results obtained with RDTs still require confi rmation by PCR, and at best are semiquantitative. Nucleic acid detection is thus the most common procedure for diagnosing viral diseases, including fi lovirus disease, because of its unsurpassed specifi city and sensitivity, and its ability to detect acute infection. Additionally, the virus does not need to be viable at the time of testing.
8

Importance of fi lovirus load determination
Real-time RT-PCR provides not only a qualitative diagnosis, but also a surrogate measure of the virus burden in a sample by determining the cycle threshold, which varies inversely with viral load. Measurement of viral load is an important parameter in Marburg virus disease and Ebola virus disease, because viral load correlates with severity of disease, survival, and infectivity. [9] [10] [11] [12] [13] [14] [15] [16] Assessing the viral load, and thus the potential infectivity of a patient, can guide triage and admission placement to minimise risk of interperson trans mission. Viral load measurements are also important to better understand the clinical presentation and pathogenesis of fi lovirus disease, and to interpret the effi cacy of candidate therapies and vaccines in animal models and human beings. [17] [18] [19] For instance, the interim analysis of a favipiravir mono therapy trial in Guinea revealed that the product might be effi cacious against Ebola virus when the cycle threshold is 20 or higher, but not when it is less than 20. 20 For the fi nal analysis, Sissoko and colleagues retested all samples with quantitative RT-PCR in a reference laboratory in France. Although the investigators observed a good correlation between cycle threshold values and RNA viral loads, they pointed out that the measured cycle threshold values might not be universally replicable, because they could vary depending on technique and technician experience, and that more robust standards are required. 21 The extent of viral load might be the key factor explaining the large variation in lethality-which is obviously among the most important metrics monitored in clinical trials-reported between diff erent fi lovirus disease outbreaks, treatment units, and times during outbreaks. Variability in lethality might also relate to factors such as time from disease onset to presentation for care, quality of care available, patient demographics, or variant of infecting virus. 14, [22] [23] [24] Accurate viral load measurement is also important in interpreting Ebola virus persistence in and transmission risk from immuneprivileged body compartments and fl uids, 25 including the male gonads or semen, [25] [26] [27] [28] eyes, 29 CNS, 30 breast milk, 31 and the intrauterine space in pregnant women. 32 Additionally, Ebola virus has occasionally been found in sweat and urine, 33 and in atypical or asymptomatic cases. 32 Similar reports note the persistence of Marburg virus in the eye, 34 semen, 35 and breast milk, 36 and in environmental samples. Viral load measurement could even be useful in assessing environmental decon tamination practices. 37 
Variability of fi lovirus load determination
Viral load assay results are subject to substantial interassay, intra-assay, inter-run, and interindividual variability. 38, 39 Additionally, interpretation of viral load is further confounded by the fact that viral load does not necessarily correlate with viable replicating fi lovirus. 40 Slight diff erences between assays or genomic templates do not substantially aff ect diagnostic performance under controlled conditions. 41 However, in general, data gathered over a long period from multiple sites-eg, within and between laboratories-cannot be compared, because each site used distinct and specifi c assays under variable conditions. 42 For instance, a 1-2 log 10 diff erence in Ebola virus viral load, which may be within the margin of error of RT-PCR testing within and between many laboratories and assays, might correlate with signifi cant diff erences in lethality.
10,12-14 Standard curves, generated by assessing multiple samples with known quantities of fi loviral RNA, can be used to measure the variability of results and off er a better understanding of the meaning of results across laboratories and time points. However, standard curves have rarely been generated under outbreak conditions, probably because of the high numbers of samples processed and to obtain and provide results rapidly.
Several real-time RT-PCR tests for Ebola virus are commercially available. Eight of these tests recently received emergency use authorisation from the US Food and Drug Administration (FDA), 43 and one received emergency use assessment and listing procedure from WHO, 44 and are commonly used in the fi eld for diagnostic 
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requiring availability and testing of numerous predefi ned standards, and is diffi cult to implement under fi eld conditions. A path forward might be gleaned from recent concerted international eff orts to develop standardised quantitative assays and reference materials for other pathogens. For instance, high quality viral load clinical and analytical assessments are now possible for DNA and other RNA viruses. 52, 53 These assessments include three major commercial methods that are approved by the FDA for the measurement of HIV-1 RNA in plasma: Amplicor Monitor, Versant HIV RNA Kit, and NucliSens HIV-1 QT System. The limits of detection for these assays range from 10-40 genome copies per mL. 53 In the fi eld of HIV/AIDS, viral load determination has become a routine test and is the basis of clinical patient management. 54 Although the commutability of some materials might need additional work to yield consensus, 55 clearly these eff orts have a positive eff ect on comparability between assays. 56 Eff orts towards standardising fi lovirus assays hold the promise of similar eff ects and should be vigorously pursued.
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We declare no competing interests. purposes (table). 8 However, none of these assays are validated for quantitative viral load assessment, and user manuals explicitly state that these assays are for qualitative purposes only. The reported sensitivities of these assays vary substantially, depending on the reagents and other materials used to assess the limits of detection. In addition to the commercial assays, various in-house quantitative assays for viral load of Ebola virus have been described, with limits of detection of approximately 1000 RNA copies per mL, but generally these assays have not been externally standardised or validated.
11,49-51 Limits of detection depend on the PCR platform used and are not uniformly reported-for instance, they can be expressed as plaque forming units, 50% tissue culture infectious dose, or copies per mL. Therefore, Cherpillod and colleagues recommended that limits of detection values be expressed in IU/mL.
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Availability of quantitative fi lovirus load assays
RT-PCR assays that provide rapid detection and RNA quantifi cation were described for several haemorrhagic fever viruses, including Ebola virus, Marburg virus, Crimean-Congo haemorrhagic fever, Lassa virus, Rift Valley fever virus, yellow fever virus, and dengue viruses 1-4. 50 The EZ1 Real-time RT-PCR Assay (US Department of Defense, USA) for Ebola virus, which uses a synthetic RNA standard, was validated by good laboratory practices for quantitative measurement of viral load in non-human primate plasma. However, this feature was omitted in the emergency use authorisation version because of increased regulatory hurdles. Although this and other such assays could potentially be validated and approved for use on human samples, the added labour and complexity of validating a quantitative assay relative to a qualitative one have substantial impediments. The Liferiver Ebola Virus Real-time RT-PCR Kit (Shanghai ZJ BioTech, China) also off ers the possibility for quantifi cation with standard dilutions prepared from a prequantifi ed positive control. However, to our knowledge, this assay is not widely used in the fi eld, although inclusion in the recent WHO emergency use assessment and listing procedure might make this assay a more popular choice. Unfortunately, only the RealStar Ebolavirus RT-PCR Kit 1.0 (Altona Diagnostics GmbH, Germany) exists for fi loviruses other than Ebola virus (table) .
Conclusions
Quantitative assessment of viral load and valid comparison of viral loads detected by various PCR platforms and laboratories are important. We advocate for the development and evaluation of standardised reagents and validated assays for fi lovirus RNA quantifi cation that are rapid, precise, easy to implement in resource-limited settings, and suffi ciently robust to operate under outbreak conditions. We recognise that validation of quantitative assays is labour intensive,
